{"id":"kx2-391-ointment-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Erythema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KX2-391 selectively inhibits Src family kinases, which are involved in inflammatory signaling pathways and keratinocyte activation in atopic dermatitis. By blocking these kinases, the drug reduces inflammatory cytokine production and abnormal skin cell proliferation, leading to improved skin barrier function and reduced itching and inflammation.","oneSentence":"KX2-391 is a Src kinase inhibitor that reduces skin inflammation and keratinocyte proliferation in atopic dermatitis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:07.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT02838628","phase":"PHASE2","title":"Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2016-04-11","conditions":"Actinic Keratosis","enrollment":168},{"nctId":"NCT03285477","phase":"PHASE3","title":"A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2017-09-18","conditions":"Actinic Keratoses","enrollment":351},{"nctId":"NCT03285490","phase":"PHASE3","title":"A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2017-09-15","conditions":"Actinic Keratosis","enrollment":351},{"nctId":"NCT03575780","phase":"PHASE1","title":"Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"Athenex, Inc.","startDate":"2018-09-07","conditions":"Actinic Keratoses","enrollment":18},{"nctId":"NCT02337205","phase":"PHASE1","title":"Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis","status":"COMPLETED","sponsor":"Athenex, Inc.","startDate":"2014-12","conditions":"Actinic Keratosis","enrollment":29}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KX2-391 Ointment 1%","genericName":"KX2-391 Ointment 1%","companyName":"Almirall, S.A.","companyId":"almirall-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KX2-391 is a Src kinase inhibitor that reduces skin inflammation and keratinocyte proliferation in atopic dermatitis. Used for Atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}